REGIONAL ANALYSIS OF A COHORT COMPASSIONATE-USE PROGRAM AND EARLY ACCESS PROGRAM WITH CABAZITAXEL PLUS PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL

被引：0
|
作者：
Malik, Z. [1 ]
di Lorenzo, G. [2 ]
Bracarda, S. [3 ]
Ardavanis, A. [4 ]
Basaran, M. [5 ]
Parente, P. [6 ]
de Schultz, W. [7 ]
Saad, F. [8 ]
van Oort, I. [9 ]
Gerritsen, W. R. [9 ]
Aparicio, L. M. Anton [10 ]
Matus, G. [11 ]
Hitier, S. [12 ]
Heidenreich, A. [13 ]
Bahl, A. [14 ]
机构：
[1] Clatterbridge Canc Ctr, Bebington, England
[2] Univ Naples Federico II, Naples, Italy
[3] ITT, Arezzo, Italy
[4] St Savas Anticanc Hosp, Athens, Greece
[5] Inst Oncol, Istanbul, Turkey
[6] Monash Univ, Fac Med, Melbourne, Vic 3004, Australia
[7] Urol Clin, Weissenfles, Germany
[8] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada
[9] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands
[10] Hosp Juan Canalejo, La Coruna, Spain
[11] Clin St Joseph, Liege, Belgium
[12] Sanofi, Chilly Mazarin, France
[13] Univ Hosp, Aachen, Germany
[14] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
111
引用
收藏
页码：37 / 37
页数：1
相关论文
共 50 条
  • [31] PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
    Eisenberger, Mario A.
    Hardy-Bessard, Arnie Claire
    Ford, Daniel
    Mourey, Loic
    Parente, Phillip
    Mainwaring, Paul N.
    Ng, Siobhan
    Alekseev, Boris
    Matveev, Vsevolod
    Caries, Joan
    Shapiro, Jeremy
    Latorzett, Igor
    Bodrogi, Stvan
    Kim, Choung-Soo
    Font, Albert
    Segal, Roanne
    Van den Berg, Hendrik Pieter
    Zhang, Wenping
    Chadjaa, Mustapha
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.
    Sartor, A. O.
    Oudard, S.
    Ozguroglu, M.
    Hansen, S.
    Machiels, J. H.
    Shen, L.
    De Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.
    Antonarakis, Emmanuel S.
    Goh, Jeffrey C.
    Gross-Goupil, Marine
    Vaishampayan, Ulka N.
    Piulats, Josep M.
    De Wit, Ronald
    Alanko, Tuomo
    Fukasawa, Satoshi
    Tabata, Kenichi
    Feyerabend, Susan
    Berger, Raanan
    Wu, Haiyan
    Kim, Jeri
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [34] Keynote-199: Updated analysis of Pembrolizumab for Metastatic Castration-Resistant Prostate Cancer (MCRPC) Previously Treated with Docetaxel
    Goh, Jeffrey C.
    Antonarakis, Emmanuel S.
    Gross-Goupil, Marine
    Vaishampayan, Ulka N.
    Piulats, Josep M.
    de Wit, Ronald
    Alanko, Tuomo
    Fukasawa, Satoshi
    Tabata, Kenichi
    Feyerabend, Susan
    Berger, Raanan
    Wu, Haiyan
    Kim, Jeri
    Poehlein, Christian H.
    de Bono, Johann S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 48 - 49
  • [35] Efficacy of abiraterone acetate in the treatment of castration-resistant prostate cancer: Early results from the German compassionate-use program
    Ohlmann, Carsten Henning
    Stoeckle, Michael
    Pfister, David A.
    Heidenreich, Axel
    Merseburger, Axel S.
    Kuczyk, Markus
    Manka, Lukas
    Hammerer, Peter
    Albers, Peter
    Arsov, Christian
    Retz, Margitta
    Gschwend, Juergen E.
    Feyerabend, Susan
    Stenzl, Arnulf
    Banek, Severine
    Marin, Jan
    Gleissner, Jochen
    Wirth, Manfred
    Zastrow, Stefan
    Heck, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana
    Christos, Paul
    Hackett, Amy
    Nordquist, Luke
    Gelmann, Edward
    Stein, Mark
    Sternberg, Cora
    Beltran, Himisha
    Gracey, Lauren
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    CANCER RESEARCH, 2019, 79 (13)
  • [37] TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL IN PORTUGAL
    Silva Miguel, L.
    Paquete, A. T.
    Guerreiro, R.
    Fiorentino, F.
    Costa, J.
    Borges, M.
    VALUE IN HEALTH, 2018, 21 : S71 - S71
  • [38] Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program
    Parente, Phillip
    Ng, Siobhan
    Parnis, Francis
    Guminski, Alex
    Gurney, Howard
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (06) : 391 - 399
  • [39] Benefit of cabazitaxel in previously treated metastatic castration-resistant prostate cancer; CARD trial
    Mishra, Ankit
    INDIAN JOURNAL OF UROLOGY, 2020, 36 (04) : 329 - 330
  • [40] Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Adesunloye, Bamidele
    Huang, Xuan
    Ning, Yangmin M.
    Madan, Ravi A.
    Gulley, James L.
    Beatson, Melony
    Kluetz, Paul Gustav
    Adelberg, David
    Arlen, Philip M.
    Parnes, Howard L.
    Mulquin, Marcia
    Steinberg, Seth M.
    Wright, John Joseph
    Trepel, Jane B.
    Dawson, Nancy Ann
    Chen, Clara
    Apolo, Andrea Borghese
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
12345